Catalent, Inc. (NYSE:CTLT) Receives Average Recommendation of “Hold” from Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have been given a consensus recommendation of “Hold” by the eleven brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $55.65.

A number of research firms recently weighed in on CTLT. Stephens reiterated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Barclays lifted their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com began coverage on shares of Catalent in a report on Sunday, June 30th. They issued a “sell” rating for the company.

Insider Transactions at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.31% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Catalent

Large investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC increased its position in shares of Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the period. Gladius Capital Management LP purchased a new position in shares of Catalent in the third quarter valued at about $28,000. GAMMA Investing LLC purchased a new position in shares of Catalent in the fourth quarter valued at about $33,000. Rakuten Securities Inc. purchased a new position in shares of Catalent in the fourth quarter valued at about $46,000. Finally, Federated Hermes Inc. purchased a new position in shares of Catalent in the fourth quarter valued at about $46,000.

Catalent Stock Up 0.6 %

Catalent stock opened at $56.51 on Friday. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20. The firm has a market capitalization of $10.23 billion, a price-to-earnings ratio of -9.26, a P/E/G ratio of 2.32 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The firm has a 50 day simple moving average of $55.59 and a 200 day simple moving average of $54.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The business had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. On average, analysts predict that Catalent will post -0.17 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.